Berberine

Berberine activates AMPK — the master metabolic switch — with trial-proven improvements in glucose, lipids, and insulin resistance comparable to metformin in some head-to-heads.

Berberine appears in herbal antimicrobial protocols with modest comparative-trial support.

Berberine promotes browning in animal models with no human browning evidence.

Berberine improves the whole atherogenic lipid pattern, lowering triglycerides and LDL alongside glucose.

Berberine acts on metabolic pathways rather than thermogenesis, with modest weight effects.

Berberine has the strongest glucose-lowering evidence of any common supplement, with effects approaching low-dose metformin.

Berberine inhibits mTOR indirectly through AMPK activation — the same energy-sensing pathway triggered by fasting and exercise — with strong metabolic evidence behind the mechanism.

Berberine improves insulin sensitivity, which indirectly stabilises hunger.

Berberine improves insulin sensitivity and produces modest weight/waist reductions in metabolic syndrome trials.

Berberine blunts postprandial glucose and improves insulin sensitivity — a metabolic moderating effect, not a true carb blocker.

Berberine produces glucose-lowering comparable to first-line oral agents in several trials, making it the strongest non-prescription option here.

Berberine improves metabolic markers with modest weight effects.

Berberine produces genuine triglyceride and glycaemic improvements in metabolic syndrome.

Berberine is the best-evidenced supplement for insulin sensitivity, with meta-analyses showing glucose and HbA1c reductions approaching metformin in some trials.

Strongest supplement option for glycemic control; prevention-specific trials are smaller but directionally positive.

Strongest supplement option for glucose tolerance specifically.

Berberine is the AMPK-linked supplement with real human outcome data, consistently lowering fasting glucose and HbA1c.

Berberine 500 mg two to three times daily lowers fasting glucose and HbA1c by clinically meaningful margins, performing comparably to metformin in head-to-head trials.

Lowering average glucose is the real mechanism, and berberine does that well.

Berberine produces consistent reductions in LDL cholesterol and triglycerides, useful as an adjunct rather than a statin replacement.

Berberine has among the strongest supplement evidence for metabolic markers, lowering fasting glucose, HbA1c and LDL cholesterol in meta-analysis. Trial quality is uneven and gastrointestinal side effects are common, but the direction of effect is consistent.

Berberine measurably reshapes gut microbial composition, but whether those shifts are beneficial or simply antimicrobial pressure is unresolved.

Berberine has the strongest supplement evidence in insulin resistance: meta-analyses show HbA1c and fasting glucose reductions approaching metformin's, with triglyceride and weight benefits. Caveats include GI side effects, variable product quality and real drug interactions.

Berberine has trial evidence for the insulin-resistance and ovulation irregularity behind PCOS-type cyst patterns — but no supplement shrinks an existing cyst, and most functional cysts need nothing but time.

Improves glucose control meaningfully, which may reduce craving-triggering post-meal dips, but no trial has measured cravings directly.

Berberine reduces HbA1c by roughly 0.7-1.0 percentage points and fasting glucose by around 1 mmol/L, with several head-to-head trials showing control comparable to metformin. It is the strongest indication berberine has, provided you can tolerate the dose and are not on interacting medication.

Improves insulin sensitivity and produces small weight reductions in metabolic syndrome, but effect sizes are modest and trial quality is variable.

Berberine improves several components of metabolic syndrome simultaneously — glucose, triglycerides, LDL and, modestly, waist circumference and blood pressure. That breadth is its main appeal here, since metabolic syndrome is a cluster rather than a single target.

Berberine-containing herbal antimicrobial protocols achieved SIBO breath-test normalisation at rates comparable to rifaximin in open-label comparative work, making it a reasonable non-antibiotic option.

A reasonable option for prediabetes alongside lifestyle change, not instead of it. Take interactions seriously.

Berberine lowers LDL cholesterol by roughly 0.4-0.6 mmol/L and triglycerides by a similar or greater margin in meta-analyses, through a mechanism entirely separate from statins. It is one of the few botanicals with lipid effects worth taking seriously — and one of the few with a drug interaction serious enough to require checking first.

In PCOS, berberine improves insulin resistance and lipid markers, and several trials report improved ovulation rates comparable to metformin. It suits the insulin-resistant PCOS phenotype specifically — and must be stopped the moment pregnancy is confirmed.